First New Smoking Cessation Drug in 20 Years: Cytisinicline Nears Market as Company Builds Commercial Team

The pharmaceutical industry's approach to nicotine addiction has remained essentially static for nearly two decades. Since varenicline received FDA approval in 2006, no new molecular entities have emerged to help the 28 million American adults who smoke cigarettes and want to quit. That drought may end next month. Achieve Life Sciences, the biotech company developing cytisinicline, announced Monday the appointment of three senior executives from Verona Pharma's successful commercial launch team, signaling confident preparation for what could become the most significant advance in tobacco cessation since the Obama administration.

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026 for cytisinicline, a plant-based alkaloid derived from laburnum seeds that has been used in Eastern Europe for smoking cessation since the 1960s. If approved, it would represent not merely an incremental improvement but a fundamental expansion of pharmacological options for the leading cause of preventable death in the United States.

Building the Commercial Infrastructure

Achieve's leadership appointments reflect methodical preparation for market entry. Christopher Martin, who served as Chief Commercial Officer at Verona Pharma during the launch of Ohtuvayre for chronic obstructive pulmonary disease, joins the board of directors. Mark Zappia, who led commercial operations during that same launch, becomes Senior Vice President of Commercial. Jim Willis, who directed the national field force at Verona, assumes the role of Vice President of Sales and Sales Enablement.

The Verona Pharma experience carries particular weight because Ohtuvayre entered a crowded COPD market against established competitors and still achieved sufficient success to attract Merck's $10.8 billion acquisition in October 2025. The team's ability to differentiate a new therapy in a saturated therapeutic category bodes well for cytisinicline's commercial prospects.

"Bringing Chris, Mark, and Jim to Achieve is one of the most consequential decisions of my first month as CEO," said Andrew Goldberg, who assumed leadership in April 2026. "Having anchored Verona Pharma's U.S. market transition, I saw firsthand the discipline and excellence this team brings to a commercial launch."

The appointments follow a financing arrangement announced earlier this spring that provided up to $354 million, including $180 million upfront and milestone-based warrants tied to FDA approval. This capital structure gives Achieve substantial runway for commercialization without immediate pressure for additional fundraising.

The Science Behind Cytisinicline

Cytisinicline operates through a mechanism similar to varenicline—partial agonism at nicotinic acetylcholine receptors—but with potentially important pharmacological distinctions. As a partial agonist, it stimulates nicotine receptors sufficiently to reduce withdrawal symptoms and cravings while blocking the full agonist effects of inhaled nicotine, making smoking less rewarding.

The Phase 3 ORCA-2 and ORCA-3 trials provided the efficacy and safety data supporting Achieve's New Drug Application. In ORCA-2, cytisinicline demonstrated statistically significant smoking cessation rates compared to placebo across multiple endpoints. The ORCA-3 trial confirmed these findings and extended the safety database. Unlike varenicline, which carries a black box warning for neuropsychiatric effects that has complicated prescribing decisions, cytisinicline's safety profile appears cleaner—though definitive comparisons await post-marketing surveillance.

The plant-based origin of cytisinicline carries both marketing and practical significance. In an era of increasing consumer skepticism toward synthetic pharmaceuticals, a naturally derived compound may resonate with patients who have resisted prescription cessation aids. Additionally, cytisinicline's decades of use in Bulgaria, Poland, and other Eastern European countries provide substantial real-world evidence supplementing the controlled trial data.

The Vaping Dimension

Perhaps the most commercially significant aspect of cytisinicline's potential approval lies beyond traditional cigarette smoking. Achieve has explicitly positioned the drug for vaping cessation—a market with virtually no approved pharmacological interventions. The 2023 National Youth Tobacco Survey found that 2.1 million middle and high school students currently use e-cigarettes, and adult vaping has increased substantially as well.

While nicotine replacement therapy and varenicline have been studied off-label for vaping cessation, no medication carries FDA approval specifically for this indication. Achieve's clinical development program included vaping-specific endpoints, and the company has signaled that vaping cessation will be a major commercial focus. This represents a classic market expansion strategy: addressing an unmet need in a growing segment rather than merely competing for share in a declining cigarette market.

The regulatory pathway for vaping cessation claims required careful navigation. The FDA's Center for Tobacco Products and Center for Drug Evaluation and Research coordinated on review standards, ensuring that cytisinicline's labeling would reflect the specific populations studied. This inter-center collaboration may establish precedents for future vaping-focused drug development.

Market Context and Competition

The smoking cessation pharmacotherapy market has contracted along with smoking prevalence, but it remains substantial. Varenicline, despite generic entry, still generates significant revenue, while bupropion and various nicotine replacement products maintain steady sales. The total addressable market for cytisinicline depends heavily on its pricing strategy and formulary positioning.

Insurance coverage will prove critical. Medicare and Medicaid smoking cessation benefits have expanded under recent legislation, but prior authorization requirements and step therapy protocols often delay access to newer medications. Achieve's commercial team will need to demonstrate cytisinicline's cost-effectiveness relative to existing options—a challenging task given that generic varenicline and bupropion are inexpensive.

The company's value proposition likely rests on efficacy advantages, better tolerability, and the vaping indication. If cytisinicline achieves even modestly superior quit rates compared to varenicline, and if its neuropsychiatric safety profile proves genuinely cleaner, these clinical distinctions could support premium pricing and favorable formulary placement despite generic competition.

Implications for Addiction Treatment

While smoking cessation might seem distinct from the substance use disorders that dominate addiction medicine discussions, tobacco dependence shares fundamental neurobiological mechanisms with other addictions. The nicotinic acetylcholine receptor system interacts extensively with dopaminergic reward pathways, and smoking frequently co-occurs with alcohol, opioid, and stimulant use disorders.

For patients in recovery from other substances, cigarette smoking represents both a continued health risk and a potential relapse trigger. Many medication-assisted treatment programs have historically deprioritized tobacco cessation, viewing nicotine as a relatively benign coping mechanism during early recovery. Growing evidence suggests this tolerance may impede long-term outcomes, as smoking maintains addiction-relevant neural circuitry and behavioral patterns.

Cytisinicline's availability could shift clinical practice in integrated addiction treatment settings. If the drug proves effective and well-tolerated in patients with complex substance use histories, it may become standard of care for concurrent tobacco cessation in residential and outpatient addiction programs. This would align with the broader movement toward comprehensive recovery support addressing all addictive behaviors rather than single-substance abstinence.

Regulatory Uncertainty

Despite the June 20 PDUFA date, approval remains uncertain. The FDA has demonstrated increasing scrutiny of CNS drugs following safety controversies with previous approvals. While cytisinicline's Eastern European track record provides reassurance, the agency may request additional safety data or impose restrictive labeling.

The political environment adds another variable. The Trump administration's approach to FDA regulation has emphasized accelerated approval pathways while simultaneously questioning certain drug safety standards. How this philosophy translates to cytisinicline's review remains unclear. The administration's broader drug policy priorities—focused primarily on synthetic opioids and supply interdiction—offer little guidance on tobacco cessation pharmacotherapy.

If approved, cytisinicline will face post-marketing requirements typical of new molecular entities, including cardiovascular outcomes studies and ongoing pharmacovigilance for neuropsychiatric effects. These commitments will shape the drug's risk-benefit profile as real-world use accumulates.

Looking Ahead

For the 480,000 Americans who die annually from smoking-related diseases, cytisinicline represents potential progress measured in lives saved rather than quarterly earnings. The drug's commercial success will depend on Achieve's execution, payer willingness to cover novel therapies, and clinician acceptance of a new option in a field long dominated by established treatments.

The Verona Pharma veterans now joining Achieve have demonstrated their ability to launch differentiated therapies in challenging markets. Whether they can replicate that success with cytisinicline will determine not only Achieve's corporate trajectory but also the range of tools available to the millions of Americans still struggling to escape nicotine addiction.